{"doi":"10.1002/cncr.35542","title":"Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT‐STS): Updated local control, late toxicities, and patient‐reported outcomes","abstract":"BACKGROUND: Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS; ClinicalTrials.gov identifier NCT03819985) investigated a radiobiologically equivalent, moderately hypofractionated course of preoperative radiotherapy (RT) 15 × 2.85 Gy in patients with soft tissue sarcoma (STS). Here, the authors report longer term follow-up to update local control and report late toxicities, as well as functional and patient-reported outcomes. METHODS: HYPORT-STS was a single-center, open-label, single-arm, prospective phase 2 clinical trial that enrolled 120 eligible adult patients with localized STS of the extremities or superficial trunk between 2018 and 2021. Patients received a 3-week course of preoperative RT followed by surgery 4-8 weeks later. End points and follow-up were analyzed from the date of surgery. RESULTS: The median follow-up was 43 months (interquartile range, 37-52 months), and the 4-year local recurrence-free survival rate was 93%. Overall RT-related late toxicities improved with time from local therapy (p < .001), and few patients had grade ≥2 toxicities (9%; n = 8 of 88) at 2 years. These included: 2% grade ≥2 skin toxicity, 2% fibrosis, 3% lymphedema, and 1% joint stiffness. Four patients (3%) had bone fractures. Both functional outcomes, as measured by the Musculoskeletal Tumor Society Rating Scale (p < .001), and quality of life, as measured by the Functional Assessment of Cancer Therapy-General (p < .001), improved with time from treatment, and both measures were better in follow-up at 2 years compared with baseline. CONCLUSIONS: Long-term follow up suggests that moderately hypofractionated preoperative RT for patients with STS is safe and effective. Higher grade late toxicities affect a minority of patients. Late toxicities decrease over time, whereas functional outcomes and health-related quality of life seem to improve with more time from combined modality treatment.","journal":"Cancer","year":2024,"id":427041,"datarank":0.6317405720069312,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.20675857039849874,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.20675857039849874,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":11,"citers_with_citation_signal":5,"citers_with_endowment":5,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9455,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03819985"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":854557,"name":"Devarati Mitra","orcid":"0000-0002-2225-164X","position":1,"is_corresponding":false},{"id":274163,"name":"Ahsan Farooqi","orcid":"0000-0001-9605-7113","position":2,"is_corresponding":false},{"id":348763,"name":"David Swanson","orcid":"0000-0003-3174-1656","position":3,"is_corresponding":false},{"id":854558,"name":"Caroline Hempel","orcid":"0000-0003-0347-5813","position":4,"is_corresponding":false},{"id":855403,"name":"Tiara Willis","orcid":null,"position":5,"is_corresponding":false},{"id":1227687,"name":"Chris Pearlnath","orcid":null,"position":6,"is_corresponding":false},{"id":105064,"name":"Wei‐Lien Wang","orcid":"0000-0001-8809-4424","position":7,"is_corresponding":false},{"id":473846,"name":"Ravin Ratan","orcid":"0000-0002-4914-7922","position":8,"is_corresponding":false},{"id":842714,"name":"Neeta Somaiah","orcid":"0000-0002-0146-7732","position":9,"is_corresponding":false},{"id":473843,"name":"Robert S. Benjamin","orcid":"0000-0002-2589-5870","position":10,"is_corresponding":false},{"id":407713,"name":"Keila E. Torres","orcid":"0000-0002-1855-0989","position":11,"is_corresponding":false},{"id":374609,"name":"Kelly K. Hunt","orcid":"0000-0001-9156-8723","position":12,"is_corresponding":false},{"id":333264,"name":"Christopher P. Scally","orcid":null,"position":13,"is_corresponding":false},{"id":72132,"name":"Emily Z. Keung","orcid":"0000-0002-8783-8484","position":14,"is_corresponding":false},{"id":854559,"name":"Robert L. Satcher","orcid":"0000-0003-3356-4331","position":15,"is_corresponding":false},{"id":854560,"name":"Justin E. Bird","orcid":"0000-0002-7537-3018","position":16,"is_corresponding":false},{"id":854561,"name":"Patrick P. Lin","orcid":"0000-0002-1460-4994","position":17,"is_corresponding":false},{"id":854562,"name":"Bryan S. Moon","orcid":"0000-0001-8612-2444","position":18,"is_corresponding":false},{"id":854563,"name":"Valerae O. Lewis","orcid":"0000-0002-3170-636X","position":19,"is_corresponding":false},{"id":105065,"name":"Christina L. Roland","orcid":"0000-0003-3400-0087","position":20,"is_corresponding":false},{"id":854556,"name":"B. Ashleigh Guadagnolo","orcid":"0000-0002-4489-7070","position":21,"is_corresponding":false},{"id":692816,"name":"Andrew J. Bishop","orcid":"0000-0002-7737-8023","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T01:58:47.805440Z","pmid":"39192597","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}